- Home
- ONDS vs PRTA Comparison
ONDS vs PRTA Comparison
Compare ONDS & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONDS
- PRTA
- Stock Information
- Founded
- ONDS 2014
- PRTA 2012
- Country
- ONDS United States
- PRTA Ireland
- Employees
- ONDS N/A
- PRTA N/A
- Industry
- ONDS Telecommunications Equipment
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- ONDS Telecommunications
- PRTA Health Care
- Exchange
- ONDS Nasdaq
- PRTA Nasdaq
- Market Cap
- ONDS 1.4B
- PRTA 472.1M
- IPO Year
- ONDS N/A
- PRTA N/A
- Fundamental
- Price
- ONDS $5.86
- PRTA $8.20
- Analyst Decision
- ONDS Strong Buy
- PRTA Buy
- Analyst Count
- ONDS 3
- PRTA 10
- Target Price
- ONDS $4.67
- PRTA $14.86
- AVG Volume (30 Days)
- ONDS 49.3M
- PRTA 1.2M
- Earning Date
- ONDS 08-12-2025
- PRTA 08-04-2025
- Dividend Yield
- ONDS N/A
- PRTA N/A
- EPS Growth
- ONDS N/A
- PRTA N/A
- EPS
- ONDS N/A
- PRTA N/A
- Revenue
- ONDS $16,131,404.00
- PRTA $10,341,000.00
- Revenue This Year
- ONDS $246.94
- PRTA N/A
- Revenue Next Year
- ONDS $161.09
- PRTA $389.77
- P/E Ratio
- ONDS N/A
- PRTA N/A
- Revenue Growth
- ONDS 75.16
- PRTA N/A
- 52 Week Low
- ONDS $0.57
- PRTA $4.32
- 52 Week High
- ONDS $6.19
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- ONDS 79.19
- PRTA 58.73
- Support Level
- ONDS $3.20
- PRTA $8.05
- Resistance Level
- ONDS $4.33
- PRTA $8.73
- Average True Range (ATR)
- ONDS 0.54
- PRTA 0.38
- MACD
- ONDS 0.17
- PRTA -0.05
- Stochastic Oscillator
- ONDS 89.02
- PRTA 47.62
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.